BiotechTube

BIM 23A760

Phase 2Terminated
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

Feb 1, 2010 → Jan 1, 2011

NCT ID
NCT01018953

About BIM 23A760

BIM 23A760 is a phase 2 stage product being developed by Ipsen for Carcinoid Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT01018953. Target conditions include Carcinoid Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT01018953Phase 2Terminated
NCT00994214Phase 2Terminated

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Somatostatin AnalogEli LillyPhase 2
52
PasireotideNovartisPhase 1
33
Pasireotide + OctreotideNovartisPhase 3
77
Pasireotide (SOM230)NovartisPhase 2
52
Octreotide + Placebo + EverolimusNovartisPhase 3
77
LutatheraNovartisPhase 2
52
EPO906 epothilone BNovartisPhase 2
52
PanitumumabAmgenPhase 2
51
AxitinibPfizerPhase 2
51
Lanreotide + Placebo (for sunitinib) + SunitinibPfizerPhase 2
51
Nivolumab + CabozantinibBristol Myers SquibbPhase 2
51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatinSanofiPhase 2/3
64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)IpsenPhase 3
74
lanreotide (Autogel formulation)IpsenApproved
82
Lanreotide + PlaceboIpsenPhase 3
74
Randomized: 40 mg Paltusotine + Randomized: 80 mg PaltusotineCrinetics PharmaceuticalsPhase 2
47
Paltusotine + PlaceboCrinetics PharmaceuticalsPhase 3
72
Telotristat etiprate + Placebo-matching telotristat etiprateLexicon PharmaceuticalsPhase 3
72
Telotristat etiprateLexicon PharmaceuticalsPhase 3
72
500 mg [14C]-LX1606Lexicon PharmaceuticalsPhase 1
28

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved
82
lanreotide acetateApproved
82
Tigan® + PlaceboApproved
82
Diosmectite (Smecta®)Approved
82
lanreotide (Autogel formulation)Approved
82